All In Biotech

Drug Trial Radar · NCT06290128

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

A Phase 3, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 109 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

109

Actual

Start

Jul 12, 2024

Primary completion

Jun 10, 2026

Study completion Oct 31, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.

Conditions

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Polyneuropathy, Inflammatory Demyelinating, Chronic

Interventions

  • RiliprubartDrug

    Pharmaceutical form: Solution Route of administration: IV Infusion

  • PlaceboDrug

    Pharmaceutical form: Solution Route of administration: IV Infusion

  • RiliprubartDrug

    Pharmaceutical form: Solution Route of administration: SC Injection

  • PlaceboDrug

    Pharmaceutical form: Solution Route of administration: SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants experiencing a responseTime frame: Baseline to week 24
  2. Percentage of participants randomized to riliprubart with lasting responseTime frame: Baseline to week 48
  3. Percentage of participants randomized to placebo who experience a responseTime frame: Week 24 to week 48

Locations

132 sites in 24 countries. Site status is shown where the registry gives one.

  • Alabama Neurology Associates- Site Number : 8400019

    Homewood, Alabama

  • USC Norris Comprehensive Cancer Center- Site Number : 8400002

    Los Angeles, California

  • University of California Irvine - Manchester Pavilion- Site Number : 8400007

    Orange, California

  • IMMUNOe International Research Centers - Centennial- Site Number : 8400049

    Centennial, Colorado

  • Yale University School of Medicine- Site Number : 8400018

    New Haven, Connecticut

  • Nova Clinical Research - Bradenton- Site Number : 8400044

    Bradenton, Florida

  • Design Neuroscience Center- Site Number : 8400053

    Miami Lakes, Florida

  • NorthShore University Health System - Glenbrook Hospital- Site Number : 8400024

    Glenview, Illinois

  • University of Kansas Medical Center- Site Number : 8400010

    Kansas City, Kansas

  • NeuroMedical Clinic of Central Louisiana- Site Number : 8400031

    Alexandria, Louisiana

  • Ochsner Medical Center - Jefferson Highway- Site Number : 8400030

    New Orleans, Louisiana

  • Johns Hopkins Hospital- Site Number : 8400015

    Baltimore, Maryland

  • Massachusetts General Hospital- Site Number : 8400009

    Boston, Massachusetts

  • Henry Ford Hospital- Site Number : 8400025

    Detroit, Michigan

  • Michigan State University- Site Number : 8400038

    East Lansing, Michigan

  • Washington University School of Medicine - Siteman Cancer Center- Site Number : 8400037

    St Louis, Missouri

  • Profound Research- Site Number : 8400052

    Las Vegas, Nevada

  • Hospital for Special Surgery - Site Number : 8400041

    New York, New York

  • Columbia University Irving Medical Center- Site Number : 8400003

    New York, New York

  • Raleigh Neurology Associates- Site Number : 8400043

    Raleigh, North Carolina

  • University of Cincinnati Medical Center- Site Number : 8400020

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center- Site Number : 8400033

    Cleveland, Ohio

  • Penn State Health Milton South Hershey Medical Center- Site Number : 8400042

    Hershey, Pennsylvania

  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022

    Philadelphia, Pennsylvania

  • Austin Neuromuscular Center- Site Number : 8400040

    Austin, Texas

  • UTHealth - The University of Texas Health Sciences Center at Houston- Site Number : 8400050

    Houston, Texas

  • University of Vermont Medical Center- Site Number : 8400012

    Burlington, Vermont

  • University of Virginia- Site Number : 8400023

    Charlottesville, Virginia

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina

  • Investigational Site Number : 0560001

    Leuven, Belgium

  • PSEG Centro de Pesquisa Clínica- Site Number : 0760009

    São Paulo, Brazil

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760017

    São Paulo, Brazil

  • Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 0760012

    Vitória, Espírito Santo, Brazil

  • Hospital Sao Rafael- Site Number : 0760011

    Salvador, Estado de Bahia, Brazil

  • Freire Pesquisa Clínica - Belo Horizonte - Rua Piauí- Site Number : 0760016

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital Moinhos de Vento- Site Number : 0760003

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760007

    Ribeirão Preto, São Paulo, Brazil

  • Investigational Site Number : 1000002

    Blagoevgrad, Bulgaria

Showing 40 of 132 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.